Deciphera Pharmaceuticals, Inc. (DCPH)

25,28 +10,63 (+72,56%) Alla chiusura: 04:00PM EDT

Deciphera Pharmaceuticals, Inc.

200 Smith Street
Waltham, MA 02451
United States
781 209 6400
https://www.deciphera.com

Settore/i: Healthcare
Settore: Drug Manufacturers - Specialty & Generic
Impiegati a tempo pieno: 355

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Steven L. Hoerter	President, CEO & Director	1,24M	N/D	1971
Mr. Thomas Patrick Kelly J.D.	Executive VP, CFO & Treasurer	772,47k	N/D	1971
Dr. Dashyant Dhanak Ph.D.	Executive VP & Chief Scientific Officer	498,45k	N/D	1963
Mr. Daniel C. Martin	Senior VP & Chief Commercial Officer	727,53k	N/D	1975
Dr. Matthew L. Sherman M.D.	Executive VP & Chief Medical Officer	870,58k	N/D	1956
Dr. Kevin Brodbeck Ph.D.	Senior VP & Chief Technical Officer	N/D	N/D	N/D
Jennifer Larson	Senior Vice President of Finance & Investor Relations	N/D	N/D	N/D
Mr. Jeffrey M. Held J.D.	Senior VP & General Counsel	N/D	N/D	N/D
Ms. Lisa Amaya Price	Senior VP & Chief Human Resources Officer	N/D	N/D	N/D
Ms. Jama Pitman	Senior VP & Chief Development Officer	N/D	N/D	1979

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di Deciphera Pharmaceuticals, Inc. al 1 aprile 2024 è 7. I criteri di valutazione fondamentali sono revisione: 7; Consiglio di Amministrazione: 6; diritti degli azionisti: 8; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.